News

Medical Diagnostics & Research

The University of Maryland School of Medicine Enters Research Collaboration with BioMark Diagnostics

The University of Maryland School of Medicine Enters Research Collaboration with BioMark Diagnostics

Equities Staff | Equities.com |

Initial focus in in accelerating assessment following glioblastoma multiforme (GBM) resection


Studies Show That Women Are Working Longer Hours Than Men

Julia Novakovich | Equities.com |

Women work around 4 hours a day at paid labor and almost 5 hours is spent in unpaid labor . This extra work is taking a toll on women’s overall health in many different ways.


uBiome, Owner of Largest Human Microbiome Database, Raises $83 Million Series C Round

Edward Kim | Equities.com |

Moving into drug discovery and development. Also adds ex Novartis CEO Joseph Jimenez to board (Image: uBiome).


Abbott Gets Rapid FDA Approval for Continuous Glucose Monitoring System

Edward Kim | Equities.com |

Eliminates the need for routine fingertip pricking.


3D Signatures (DXD.V) Breakthrough Alzheimer's ID Test Confirming Accuracy of its Diagnostic Tools

Edward Kim | Equities.com |

3D Signatures announced clinical results demonstrating that it can identify patients with Alzheimer's and the stage of the disease brings hope to many families effected by the disease.


Invictus MD announces binding LOI to acquire 100% of a Late Stage Applicant under Health Canada’s ACMPR

Spotlight Companies | Equities.com |

​Invictus MD Strategies Corp. (CSE:IMH OTC:IVITF FRA: 8IS) is pleased to announce that on February 6, 2017 it had entered into a binding letter of intent (“LOI”)


MabVax Begins Enrollment of Pancreatic Cancer Patients For Phase I Clinical Trial Expansion

Destiny A. Lopez | Equities.com |

MabVax is on a mission to address those needs and, effectively, usher in cancer treatment into the 21st century.


Cellectar Biosciences Aims to Close 2016 on A High Note Thanks to Recent Key Developments

Destiny A. Lopez | Equities.com |

Cellectar Biosciences develops targeted phospholipid drug conjugates to help usher the treatment and imaging of cancer into the 21st century.


NeoGenomics (NEO) Offers a One-Stop-Shop for Cancer Research Partners

Bolton Flautt | Equities.com |

Comprehensive testing is invaluable when it comes to cancer research. About 595,690 Americans are expected to die of cancer in 2016, which translates to about 1,630 people per day. Cancer is the second most common cause of death in the US, exceeded only by


VolitionRx Ltd is Revolutionizing Cancer Diagnosis With Noninvasive Diagnostic Tests

Destiny A. Lopez | Equities.com |

VolitionRx Ltd is dedicated to revolutionizing cancer diagnosis by developing noninvasive diagnostic tests based on its Nucleosomics® technology.